Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non-Current Assets (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Non-Current Assets data on record, last reported at $58.0 million in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 9.16% year-over-year to $58.0 million; the TTM value through Sep 2025 reached $240.4 million, down 9.42%, while the annual FY2024 figure was $61.3 million, 9.25% down from the prior year.
  • Non-Current Assets reached $58.0 million in Q3 2025 per GLUE's latest filing, down from $60.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $70.5 million in Q2 2023 and bottomed at $58.0 million in Q3 2025.
  • Average Non-Current Assets over 3 years is $64.9 million, with a median of $66.2 million recorded in 2024.
  • Peak YoY movement for Non-Current Assets: fell 1.11% in 2024, then dropped 10.03% in 2025.
  • A 3-year view of Non-Current Assets shows it stood at $67.5 million in 2023, then dropped by 9.25% to $61.3 million in 2024, then dropped by 5.33% to $58.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $58.0 million in Q3 2025, $60.1 million in Q2 2025, and $60.9 million in Q1 2025.